Standard BioTools Inc. (NASDAQ: LAB) announced on October 5, 2026, that it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The transaction is expected to close in approximately 30 days, subject to customary closing conditions. Until the deal is finalized, the Microfluidics business will continue to operate as a part of Standard BioTools.
Standard BioTools President and Chief Executive Officer Michael Egholm, PhD, stated that ARCHIMED brings deep healthcare and life sciences expertise, a strong understanding of the market, and the resources to support the business’s next chapter. He noted that the sale marks an important step in the strategic actions the company has outlined for its shareholders.
The filing includes a standard set of forward-looking statements regarding the transaction. These statements identify risks such as the possibility that the sale may not be completed in a timely manner or at all, that conditions to the closing may not be satisfied, or that the agreement could be terminated, potentially requiring Standard BioTools to pay a termination fee. The company also referenced other ongoing transactions, including a proposed deal with Treeline Biosciences and the sale of its Mass Cytometry business to Element Biosystems, LLC.
